Publications
Detailed Information
Spontaneous reporting of adverse drug events by Korean Regional Pharmacovigilance Centers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Yoo Seob | - |
dc.contributor.author | Lee, Yong-Won | - |
dc.contributor.author | Choi, Young Hwa | - |
dc.contributor.author | Park, Byungjoo | - |
dc.contributor.author | Choi, Sung-Kyu | - |
dc.contributor.author | Park, Jung-Won | - |
dc.contributor.author | Hong, Chein-Soo | - |
dc.contributor.author | Kim, Eung-Gyu | - |
dc.contributor.author | Jee, Young Koo | - |
dc.date.accessioned | 2012-06-08T07:23:04Z | - |
dc.date.available | 2012-06-08T07:23:04Z | - |
dc.date.issued | 2009-10 | - |
dc.identifier.citation | PHARMACOEPIDEMIOLOGY AND DRUG SAFETY; Vol.18 10; 910-915 | ko_KR |
dc.identifier.issn | 1053-8569 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76914 | - |
dc.description.abstract | Purpose Patterns of prescriptions are markedly influenced by regional disease entities, medical education, culture, economic status, and available pharmaceutical companies. Features of adverse drug reactions (ADRs) may vary in different countries. In this study, we analyzed the causative drugs and clinical manifestations of spontaneously reported ADRs in Korea. Methods Six Korean Regional Pharmacovigilance Centers collected 1418 cases of spontaneously reported adverse drug events (ADES) by doctors, pharmacists, and nurses, and the clinical features and causative drugs were evaluated. The data were collected from general hospitals (76.5%), primary clinics, and pharmacies (23.5%). Results Based upon the World Health Organization (WHO)-Uppsala Monitoring Center criteria (certain-13.7%, probable-46.1%, possible-32.1%), 91.9% of the collected events were suspected to be ADRs and 15.8% of patients experienced serious ADRs. The most prevalent causative drugs were antibiotics (31.6%), followed by contrast dyes (14.0%), non-steroidal anti-inflammatory drugs (NSAIDs) (11.1%), anti-psychotics (5.4%), anti-convulsants (5.2%), cardiovascular agents (4.8%), anti-neoplastics (4.6%), and opiates and non-opiate pain killers (3.5%). Among the antibiotics, cephalosporins (8.1%) were the most common, followed by anti-tuberculosis agents (5.7%), quinolones (4.0%), vancomycin (3.1%), and penicillin (2.8%). The most common side effect was skin manifestations, which were seen in 42% of the patients, followed by neurologic manifestations (14%), gastrointestinal involvements (12.9%), generalized reactions (9.4%), and respiratory involvements (4.5%). Conclusion Antibiotics, contrast dyes, and NSAIDs were the most common causative drugs for ADRs, which reflects the prescription pattern and the prevalence of diseases in Korea. These data may be useful in establishing a Korean pharmacovigilance system. Copyright (C) 2009 John Wiley & Sons, Ltd. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | JOHN WILEY & SONS LTD | ko_KR |
dc.subject | adverse drug reaction | ko_KR |
dc.subject | Regional Pharmacovigilance Center | ko_KR |
dc.subject | spontaneous reporting | ko_KR |
dc.title | Spontaneous reporting of adverse drug events by Korean Regional Pharmacovigilance Centers | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 신유섭 | - |
dc.contributor.AlternativeAuthor | 이용원 | - |
dc.contributor.AlternativeAuthor | 최영화 | - |
dc.contributor.AlternativeAuthor | 박병주 | - |
dc.contributor.AlternativeAuthor | 지영구 | - |
dc.contributor.AlternativeAuthor | 최성규 | - |
dc.contributor.AlternativeAuthor | 김응규 | - |
dc.contributor.AlternativeAuthor | 박정원 | - |
dc.contributor.AlternativeAuthor | 홍천수 | - |
dc.identifier.doi | 10.1002/pds.1796 | - |
dc.citation.journaltitle | PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | - |
dc.description.citedreference | Eliasson E, 2006, BRIT MED J, V332, P1163 | - |
dc.description.citedreference | Camargo AL, 2006, EUR J CLIN PHARMACOL, V62, P143, DOI 10.1007/s00228-005-0086-7 | - |
dc.description.citedreference | Classen DC, 2005, QUAL SAF HEALTH CARE, V14, P221, DOI 10.1136/qshc.2002.002972 | - |
dc.description.citedreference | CLASSEN DC, 2005, QUAL SAF HEALTH CARE, V14, P225 | - |
dc.description.citedreference | Stricker BHC, 2004, BRIT MED J, V329, P44 | - |
dc.description.citedreference | CHOI JH, 2004, KOREAN J MED, V67, P290 | - |
dc.description.citedreference | Thong BYH, 2003, ANN ALLERG ASTHMA IM, V90, P342 | - |
dc.description.citedreference | Lacoste-Roussillon C, 2001, CLIN PHARMACOL THER, V69, P458 | - |
dc.description.citedreference | DEMOLY P, 2001, CURR OPIN ALLERGY CL, V1, P305 | - |
dc.description.citedreference | Edwards IR, 2000, LANCET, V356, P1255 | - |
dc.description.citedreference | Gandhi TK, 2000, J GEN INTERN MED, V15, P149 | - |
dc.description.citedreference | Bates DW, 1999, ARCH INTERN MED, V159, P2553 | - |
dc.description.citedreference | Roughead EE, 1998, MED J AUSTRALIA, V168, P405 | - |
dc.description.citedreference | Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200 | - |
dc.description.citedreference | Hunziker T, 1997, ALLERGY, V52, P388 | - |
dc.description.citedreference | Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301 | - |
dc.description.citedreference | BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29 | - |
dc.description.citedreference | RAWLINS MD, 1995, J ROY COLL PHYS LOND, V29, P41 | - |
dc.description.citedreference | LEAPE LL, 1991, NEW ENGL J MED, V324, P377 | - |
dc.description.citedreference | BERRY LL, 1988, AM J HOSP PHARM, V45, P1534 | - |
dc.description.citedreference | FAICH GA, 1986, NEW ENGL J MED, V314, P1589 | - |
dc.description.citedreference | JICK H, 1984, J ALLERGY CLIN IMMUN, V74, P555 | - |
dc.description.tc | 4 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.